Menopause-related brain fog is a collection of temporary cognitive changes that many women experience during perimenopause and menopause While scrolling on social media, you may have come across content claiming that testosterone is the ultimate fix for menopause-related brain fog.
Social media has been rife with claims testosterone helps with menopause, but a new study finds insufficient evidence Testosterone has shown “insufficient” evidence to support social media claims that it can improve certain symptoms linked to the menopause, according to…
Testosterone enhancers are commonly used supplements that increase natural testosterone production in males. These supplements can aid in muscle development, enhance endurance and vitality, raise sex drive, and improve overall well-being. Much like the soil essential for nurturing a money…
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes. Night sweats are a common manifestation of menopause, but rapid symptom onset, drenching episodes, and accompanying systemic symptoms may indicate…
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors. Investigational CagriSema was associated with mean weight reductions ranging from 23.1% to 26.7% across menopause stages at 68 weeks, with additional improvements in waist circumference and…
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data. Among 410 US participants, 66.9% of women receiving elinzanetant 120 mg daily achieved at least a 50% reduction in VMS frequency…
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains. Women who reported more frequent physical activity experienced significantly lower perimenopause symptom burden across psychological, somatic, and urogenital domains, according to…
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms. For PCPs, Pinkerton recommended setting expectations at treatment initiation: symptom relief may begin quickly and continue to build, while early…
TMS 2026: JoAnn Pinkerton, MD, discusses elinzanetant's onset of VMS relief, common adverse effects, and treatment expectations for primary care physicians. Primary care physicians prescribing elinzanetant for menopause-related vasomotor symptoms (VMS) should counsel patients about the potential for early symptom relief,…
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study. Women receiving menopause hormone therapy (HT) alongside semaglutide experienced significantly greater weight loss than those taking semaglutide…
Reproductive health, pregnancy, menopause, and gynecologic care advances.
An article joins this feed when it matches these terms. Each one is also a search of its own.